GlassScriptPhysician profile
Abdul W Mughal
NPI 1003877440
$3,618.43
in general payments reported to CMS, 2019-2025
42 companies · $999 in 2025
The $999 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $687 · 2020: $124 · 2021: $29.07 · 2022: $171 · 2023: $591 · 2024: $1,017 · 2025: $999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,218 · Education: $390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,217.52 |
| Education | $390.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $411.83 | 2019-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $383.74 | 2019-2025 | Opdivo, Opdualag, Augtyro |
| Astrazeneca Pharmaceuticals LP | $307.95 | 2019-2025 | Tagrisso, Calquence, Imfinzi |
| Astellas Pharma US INC | $257.32 | 2020-2025 | Xospata, Vyloy, Padcev |
| Eisai INC. | $233.92 | 2019-2025 | |
| Lilly USA, LLC | $148.66 | 2019-2025 | Verzenio, Jaypirca, Zepbound |
| Incyte Corporation | $139.56 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $137.20 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $130.85 | 2019-2025 | |
| Pfizer INC. | $125.72 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $107.66 | 2019-2025 | |
| Daiichi Sankyo INC. | $84.37 | 2022-2024 | Injectafer, Enhertu |
| Janssen Biotech, INC. | $79.19 | 2022-2025 | Carvykti, Erleada, Talvey |
| Celgene Corporation | $73.09 | 2019-2024 | |
| Sobi, INC | $72.70 | 2023-2025 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Mughal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.